Biotalys (Euronext: BTLS) (the "Company" or "Biotalys"), today announced it has successfully obtained subscription commitments for new shares for an amount of EUR 12,050,000 through a private placement ("Private Placement").
The Private Placement involves the issue of 7,875,811 new shares (rounded 20.96% of the Company's shares outstanding prior to the transaction) at an issue price of EUR 1.53 per share, representing a discount of 40% compared to the volume weighted average price of the Company's share on Euronext Brussels during the period of 30 days from (and including) 1 April 2026 till (and including) 30 April 2026.
Investors participating in the Private Placement are current shareholders, including Ackermans & van Haaren NV, Agri Investment Fund BV, ASR Vermogensbeheer NV, Federale Participatie- en Investeringsmaatschappij NV, GIMV NV, PMV NV, Sofinnova Industrial Biotech I, and the Flemish Institute for Biotechnology VIB.
Simon Moroney, Chairman of Biotalys, said: "On behalf of the board, I welcome this additional financing by our long-term reference shareholders. These investors support our view that there's an urgent and growing need for safe, efficacious and cost-competitive biocontrol solutions that can replace conventional chemistry. This investment reflects a conviction that our technology is well- positioned to address this need and that scalable, fermentation-based biocontrols are essential to the future of sustainable crop protection."
Carlo Boutton, interim CEO of Biotalys, commented: "We are grateful for the continued confidence and commitment shown by our key investors through this capital raise. Their support enables Biotalys to develop its unique precision biocontrol solutions and bring these to growers, starting with the U.S. and Europe. With this strengthened capital base, we are well positioned to advance our innovative pipeline and create sustainable value for agriculture and its stakeholders. We look forward to building the future of crop protection together."
Biotalys is developing precision biocontrol solutions based on proteins for the protection of crops in both the pre- and post-harvest markets. The Company provides novel solutions that bridge the efficacy and scale of chemistry with the environmental advantages of biological solutions. Based on its novel AGROBODY™ technology platform, Biotalys is developing a focused pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate.
Biotalys intends to use the proceeds of the Private Placement as follows:
To fund the progress of the Company's most advanced biofungicide programs, EVOCA™ NG and BioFun-6, including through further process development, field trials and the conducting of regulatory processes;
To fund the ongoing platform development and intellectual property capture to maintain competitiveness and increase the efficiency of Biotalys' 2.0 AGROBODY Foundry™ platform;
To support the retention of key talent; and
For general business purposes.
Biotalys aims to reach the following value inflection points in the near future: regulatory approval of EVOCA in the European Union, paving the way for the regulatory submission of the second generation of the biocontrol, EVOCA NG; product registration of EVOCA in California; successful field trials with a BioFun-6 lead candidate; progress in finetuning its production process and manufacturing capabilities to achieve commercially competitive manufacturing costs for its product pipeline, supported by its strategic partnership with 21st.BIO; and progress in the ongoing collaborations with Syngenta (BioIns-2), the Gates Foundation (BioFun-7) and its partner in the post-harvest market AgroFresh.
The payment and delivery of the ...
